Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy With Concurrent Durvalumab vs. Cetuximab in Locoregionally Advanced Head and Neck Cancer
NCT03258554Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 3 trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Apr 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03258554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258554.